Tags

Type your tag names separated by a space and hit enter

Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo.
Contraception. 2008 Feb; 77(2):91-6.C

Abstract

BACKGROUND

The study was conducted to evaluate the effects of a 91-day extended-regimen oral contraceptive (OC) containing levonorgestrel (LNG) with low-dose ethinyl estradiol (EE) in place of placebo on endometrial histology.

STUDY DESIGN

Endometrial biopsies were obtained prior to initiation and posttreatment, between cycle Days 60 and 84 (during combination EE/LNG tablets), between cycle Days 85 and 91 (during low-dose EE tablets) or after completion of therapy.

RESULTS

Paired endometrial biopsy samples obtained before and after treatment were available for 63 subjects. Biopsy results demonstrated that this OC regimen did not promote unexpected changes in the endometrium, either during the course of active treatment with EE/LNG or during the 7-day low-dose EE interval. Endometrial hyperplasia or malignancy was not observed in any endometrial biopsy sample.

CONCLUSION

Use of a 91-day extended-regimen OC with low-dose EE in place of placebo was not associated with any untoward effects on the endometrium.

Authors+Show Affiliations

Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507-1627, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18226671

Citation

Anderson, Freedolph D., et al. "Endometrial Effects of a 91-day Extended-regimen Oral Contraceptive With Low-dose Estrogen in Place of Placebo." Contraception, vol. 77, no. 2, 2008, pp. 91-6.
Anderson FD, Feldman R, Reape KZ. Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo. Contraception. 2008;77(2):91-6.
Anderson, F. D., Feldman, R., & Reape, K. Z. (2008). Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo. Contraception, 77(2), 91-6. https://doi.org/10.1016/j.contraception.2007.11.006
Anderson FD, Feldman R, Reape KZ. Endometrial Effects of a 91-day Extended-regimen Oral Contraceptive With Low-dose Estrogen in Place of Placebo. Contraception. 2008;77(2):91-6. PubMed PMID: 18226671.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo. AU - Anderson,Freedolph D, AU - Feldman,Robert, AU - Reape,Kathleen Z, Y1 - 2008/01/11/ PY - 2007/07/10/received PY - 2007/09/14/revised PY - 2007/11/15/accepted PY - 2008/1/30/pubmed PY - 2008/5/13/medline PY - 2008/1/30/entrez SP - 91 EP - 6 JF - Contraception JO - Contraception VL - 77 IS - 2 N2 - BACKGROUND: The study was conducted to evaluate the effects of a 91-day extended-regimen oral contraceptive (OC) containing levonorgestrel (LNG) with low-dose ethinyl estradiol (EE) in place of placebo on endometrial histology. STUDY DESIGN: Endometrial biopsies were obtained prior to initiation and posttreatment, between cycle Days 60 and 84 (during combination EE/LNG tablets), between cycle Days 85 and 91 (during low-dose EE tablets) or after completion of therapy. RESULTS: Paired endometrial biopsy samples obtained before and after treatment were available for 63 subjects. Biopsy results demonstrated that this OC regimen did not promote unexpected changes in the endometrium, either during the course of active treatment with EE/LNG or during the 7-day low-dose EE interval. Endometrial hyperplasia or malignancy was not observed in any endometrial biopsy sample. CONCLUSION: Use of a 91-day extended-regimen OC with low-dose EE in place of placebo was not associated with any untoward effects on the endometrium. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/18226671/Endometrial_effects_of_a_91_day_extended_regimen_oral_contraceptive_with_low_dose_estrogen_in_place_of_placebo_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0010-7824(07)00503-3 DB - PRIME DP - Unbound Medicine ER -